Predict your next investment

Venture Capital
borealis.vc

See what CB Insights has to offer

Investments

95

Portfolio Exits

20

Funds

5

Partners & Customers

1

About Borealis Ventures

Borealis Ventures partners closely with exceptional entrepreneurs to build market-defining companies. Its focus is on the opportunities to transform healthcare through new therapies, digital innovation, and other technologies.

Borealis Ventures Headquarter Location

10 Allen St., Upper Level

Hanover, New Hampshire, 03755,

United States

603.643.1500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Borealis Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Borealis Ventures in 1 Expert Collection, including Travel Technology (Travel Tech).

T

Travel Technology (Travel Tech)

39 items

Tech-enabled companies offering services and products focused on tourism. This collection includes booking services, search platforms, on-demand travel and recommendation sites, among others.

Latest Borealis Ventures News

ReNetX Bio Completes Enrollment of RESET Study of AXER-204 for Chronic Spinal Cord Injury

Nov 16, 2021

Series B Proceeds Will Advance Ankyra’s lead molecule into the Clinic while Expanding Ankyra’s Tumor-Localized Immuno-Oncology Pipeline  New Investors include Borealis Ventures, Fidelity Management & Research Company LLC, GV, Sands Capital Ventures, and Spring Mountain Capital and Existing Investors Polaris Partners and Mithril Capital Newly appointed Chief Medical Officer, Dr. Howard L. Kaufman, will lead clinical development November 12, 2021 08:00 AM Eastern Standard Time BOSTON--( BUSINESS WIRE )--Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, today announced the closing of a $45 million Series B financing. Proceeds from the financing will be used to progress Ankyra’s lead molecule, ANK-101 through Investigational New Drug (IND) enabling studies and into Phase 1 clinical trials, as well as advance additional cytokine programs. Several new investors including Borealis Ventures, Fidelity Management & Research Company LLC, GV, Sands Capital Ventures, and Spring Mountain Capital joined existing investors Polaris Partners and Mithril Capital. In connection with the closing of the financing, Phil Ferneau of Borealis Ventures will join the Ankyra Therapeutics Board of Directors. Ankyra Therapeutics has developed a highly differentiated technology platform that significantly expands the therapeutic window of immune-modulating oncology drugs by forming an extended drug depot following intratumoral administration. The company is rapidly progressing its lead molecule into clinical studies. “We are fortunate to have the support of investors who share our vision of developing tumor-localized cytokines and other immune therapies to treat cancer with enhanced efficacy and safety,” said Tillman Gerngross, Co-founder, and Executive Chairman of Ankyra Therapeutics. “This is an important moment for the company as we work to bring our first development program through IND and into Phase 1 clinical trials, and we are excited to bring Howard Kaufman, and his proven track record of successful clinical development, to the Ankyra team.” Dr. Kaufman has been a leading authority on tumor immunotherapy and oncolytic viruses for the treatment of melanoma. He led the first successful phase III trial of an intratumoral agent resulting in FDA approval for the treatment of melanoma. He served as president of the Society for Immunotherapy of Cancer (SITC) from 2014-2016. Prior to joining Ankyra, Dr. Kaufman was Head of Research and Development at Immuneering Corporation. Dr. Kaufman also served as chief medical officer at Replimune Group, Inc., where he oversaw the strategic development of the company’s pipeline. “Systemic treatment with cytokines and other immune agonists has been limited by broad immune activation and systemic toxicity. Intratumoral administration can improve the therapeutic window of immune activating drugs, but the approach has been limited by rapid clearance from the tumor microenvironment. There is a significant need for approaches that improve the therapeutic window and reduce the frequency of dosing. Ankyra’s approach is a true platform that can extend drug bioavailabity and enhance anti-tumor immune responses, while avoiding systemic adverse events. We look forward to extending our preclinical observations into cancer patients in our upcoming Phase 1 clinical trial,” stated Howard Kaufman, Chief Medical Officer of Ankyra. About Ankyra Therapeutics Ankyra Therapeutics is a biotechnology company that has developed a highly differentiated technology platform that expands the therapeutic window of cytokine drugs by forming a stable depot in the tumor after local administration leading to prolonged immune activation and potent local and systemic immunity with reduced systemic toxicity. Ankyra was founded in 2019 and is headquartered in Boston, Massachusetts. For more information, please visit www.ankyratx.com Contacts

Borealis Ventures Investments

95 Investments

Borealis Ventures has made 95 investments. Their latest investment was in Amagma Therapeutics as part of their Unattributed VC on June 6, 2022.

CBI Logo

Borealis Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/1/2022

Unattributed VC

Amagma Therapeutics

$2.28M

Yes

1

1/20/2022

Series B

Blue Rabbit Ventures

$13.64M

Yes

1

9/8/2021

Series B

Ankyra Therapeutics

$45M

Yes

2

7/20/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/18/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/1/2022

1/20/2022

9/8/2021

7/20/2021

2/18/2021

Round

Unattributed VC

Series B

Series B

Series B

Series C

Company

Amagma Therapeutics

Blue Rabbit Ventures

Ankyra Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$2.28M

$13.64M

$45M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

2

10

10

Borealis Ventures Portfolio Exits

20 Portfolio Exits

Borealis Ventures has 20 portfolio exits. Their latest portfolio exit was Avitide on September 16, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

9/16/2021

Acquired

$99M

4

7/21/2021

Acquired

$99M

8

6/23/2020

Reverse Merger

$99M

1

2/14/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

2/8/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/16/2021

7/21/2021

6/23/2020

2/14/2019

2/8/2019

Exit

Acquired

Acquired

Reverse Merger

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

4

8

1

10

10

Borealis Ventures Acquisitions

2 Acquisitions

Borealis Ventures acquired 2 companies. Their latest acquisition was Vico Software on March 23, 2007.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/23/2007

Series B

$99M

$3.6M

Acquired

6/30/2004

Private Equity

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/23/2007

6/30/2004

Investment Stage

Series B

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$3.6M

Note

Acquired

Subscribe to see more

Sources

10

Borealis Ventures Fund History

5 Fund Histories

Borealis Ventures has 5 funds, including Vox Health Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/27/2020

Vox Health Fund

$12.05M

1

9/6/2018

Built Environment Innovation Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

12/5/2012

Borealis Granite Fund

Subscribe to see more

Subscribe to see more

$99M

10

5/30/2003

The Borealis Fund LP

Subscribe to see more

Subscribe to see more

$99M

10

Borealis Ventures II

Subscribe to see more

Subscribe to see more

10

Closing Date

1/27/2020

9/6/2018

12/5/2012

5/30/2003

Fund

Vox Health Fund

Built Environment Innovation Fund LP

Borealis Granite Fund

The Borealis Fund LP

Borealis Ventures II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$12.05M

$99M

$99M

$99M

Sources

1

10

10

10

10

Borealis Ventures Partners & Customers

1 Partners and customers

Borealis Ventures has 1 strategic partners and customers. Borealis Ventures recently partnered with Johnson & Johnson, and Dartmouth College on November 11, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

11/27/2017

Partner

United States

News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners).

`` It will be an active partnership with Johnson & Johnson and Borealis Ventures .

1

Date

11/27/2017

Type

Partner

Business Partner

Country

United States

News Snippet

News from Borealis Ventures Motorola Invests in Handmark. (acquired by AIG Alteris Health Partners).

`` It will be an active partnership with Johnson & Johnson and Borealis Ventures .

Sources

1

Borealis Ventures Team

3 Team Members

Borealis Ventures has 3 team members, including current Founder, Managing Partner, Phil Ferneau.

Name

Work History

Title

Status

Jesse Devitte

Founder

Current

Phil Ferneau

Founder, Managing Partner

Current

Matt Rightmire

Managing Director

Current

Name

Jesse Devitte

Phil Ferneau

Matt Rightmire

Work History

Title

Founder

Founder, Managing Partner

Managing Director

Status

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.